The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Psychiatric Complications of Long-term Interferon Alfa Therapy
Abstract
Ten (17%) of 58 patients with chronic viral hepatitis treated with a four- to 12-month course of recombinant human interferon alfa developed psychiatric side effects. The psychiatric side effects fell into three categories: an organic personality syndrome characterized by irritability and short temper; an organic affective syndrome marked by extreme emotional lability, depression, and tearfulness; and a delirium marked by clouding of consciousness, agitation, paranoia, and suicidal potential. These psychiatric side effects appeared after one to three months of therapy, usually improved within three to four days of decreasing the dose of interferon alfa, and invariably resolved once therapy was stopped. The organic personality and affective syndromes tended to occur in patients who received the highest dose of interferon alfa, who had relatively mild hepatitis, and who lost weight during interferon treatment. Delirium tended to occur in patients with severe hepatitis who had previous evidence of organic brain injury or dysfunction or previous drug and alcohol abuse. Failure to recognize these side effects quickly and to treat them with supportive therapy and modification of the dose of interferon alfa could result in limitation of therapy and serious personal and interpersonal consequences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A pivotal study in 1987 reported that a subpopulation of people with viral hepatitis treated with interferon (IFN) α — a pro-inflammatory anti-viral cytokine13 — developed depression14, demonstrating that a pro-inflammatory molecule in the periphery could directly influence mood.”
From Central regulation of stress-evoked peripheral immune responses (2023) · cites this paper as [14]
Citations
Cites
Stewart, W. E. (1979) · Springer eBooks · doi:10.1007/978-3-7091-3432-0 · Cited by 1,158
The Concept of a Blood-Brain Barrier
(1980) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(80)90073-7 · Cited by 790
Talpaz, M., Kantarjian, H. M., McCredie, K., Trujillo, J. M., Keating, M. J., & Gutterman, J. U. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604243141701 · Cited by 647
GUTTERMAN, J. U., FINE, S., QUESADA, J., HORNING, S. J., LEVINE, J. F., ALEXANIAN, R., BERNHARDT, L., KRAMER, M., SPIEGEL, H., COLBURN, W., et al. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-5-549 · Cited by 377
Renal cell carcinoma: antitumor effects of leukocyte interferon.
Quesada, J. R., Swanson, D. A., Trindade, A., & Gutterman, J. U. (1983) · PubMed · Cited by 314
Neuropsychiatric Manifestations of Human Leukocyte Interferon Therapy in Patients With Cancer
Adams, F. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03350070056026 · Cited by 260
Mechanisms of fever induced by recombinant human interferon.
Dinarello, C. A., Bernheim, H. A., Duff, G. W., Le, H. V., Nagabhushan, T. L., Hamilton, N. C., & Coceani, F. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111508 · Cited by 226
Neurological effects of recombinant human interferon.
Smedley, H., Katrak, M., Sikora, K., & Wheeler, T. (1983) · BMJ · doi:10.1136/bmj.286.6361.262 · Cited by 223
Central nervous system toxicity of interferon
Rohatiner, A. Z., Prior, P. F., Burton, A. C., Smith, A. T., Balkwill, F. R., & Lister, T. A. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.63 · Cited by 183
Scott, G. M., Secher, D. S., Flowers, D., Bate, J., Cantell, K., & Tyrrell, D. A. J. (1981) · BMJ · doi:10.1136/bmj.282.6273.1345 · Cited by 170
Cited by
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Cytokines and the Brain: Implications for Clinical Psychiatry
Kronfol, Z., & Remick, D. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.683 · Cited by 784
Bercik, P., Verdu, E. F., Foster, J. A., Macri, J., Potter, M., Huang, X., Malinowski, P., Jackson, W., Blennerhassett, P., Neufeld, K. A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.063 · Cited by 674
Metadata
- Authors
- Renault, P. F.
- Affiliations
- National Cancer Institute (US)
- Corresponding author
- Renault, Pierre F.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1987-09-01
- Volume
- 147
- Issue
- 9
- Pages
- 1577
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2087704532
- Cited by
- 413
- References
- 16
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 10 · 2022: 8 · 2021: 15 · 2020: 13 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 11 · 2014: 7 · 2013: 4 · 2012: 10
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- interferon-alpha, psychiatric adverse effects, chronic viral hepatitis, delirium, depression, irritability, paranoia, dose reduction, drug-induced psychosis
- MeSH terms
- Adult, Affective Symptoms, Aged, Clinical Trials as Topic, Delirium, Female, Hepatitis, Chronic, Humans, Interferon Type I, Male, Middle Aged, Personality Disorders, Psychoses, Substance-Induced, Random Allocation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychiatric Complications of Long-term Interferon Alfa Therapy. https://app.cochat.ai/papers/10.1001/archinte.1987.00370090055011
- The paper
- Renault, P. F. (1987). Psychiatric Complications of Long-term Interferon Alfa Therapy. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1987.00370090055011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.